» Articles » PMID: 35178154

Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung Adenocarcinoma

Overview
Publisher Wiley
Date 2022 Feb 18
PMID 35178154
Authors
Affiliations
Soon will be listed here.
Abstract

Immune checkpoint genes (ICGs) play pivotal roles in tumor immune microenvironment (TIME), and thus, targeting them represents a promising strategy for cancer immunotherapy. However, the genetic landscape of ICGs in lung adenocarcinoma (LUAD) is still unknown. Herein, we comprehensively evaluated the ICG expression profiles of 1439 LUAD samples and linked ICG expression patterns with infiltration of immune cells, clinical features, and response to immune checkpoint blockade (ICB). The ICGscore was developed to quantify ICG expression patterns of individual patient by principal component analysis algorithms. Three distinct ICG expression patterns and three ICG-related genomic clusters were determined, which were implicated in different clinical outcomes, level of immune infiltrates, and biological process. LUAD patients were subdivided into high- and low-ICGscore subgroups. Patients with higher ICGscore were characterized by favorable survival outcomes, increased immune cell infiltration, and enhanced expression of ICGs. Further analysis revealed that lower ICGscore was associated with greater tumor mutation loads and higher mutation rates of , , and . High ICGscore has the potential to be a robust indicator in clinical benefit of immunotherapy. Taken together, unraveling the ICG expression patterns will advance our understanding of heterogeneity of TIME and guides more effective immunotherapeutic strategies in LUAD.

Citing Articles

Deciphering key roles of B cells in prognostication and tailored therapeutic strategies for lung adenocarcinoma: a multi-omics and machine learning approach towards predictive, preventive, and personalized treatment strategies.

Zhang J, Hu D, Fang P, Qi M, Sun G EPMA J. 2025; 16(1):127-163.

PMID: 39991096 PMC: 11842682. DOI: 10.1007/s13167-024-00390-4.


Construction and validation of prognostic signatures related to mitochondria and macrophage polarization in gastric cancer.

Zhang Y, Cao J, Yuan Z, Zuo H, Yao J, Tu X Front Oncol. 2024; 14:1433874.

PMID: 39132501 PMC: 11310369. DOI: 10.3389/fonc.2024.1433874.


Characterization of an endoplasmic reticulum stress-associated lncRNA prognostic signature and the tumor-suppressive role of RP11-295G20.2 knockdown in lung adenocarcinoma.

Yu L, Zhou S, Hong W, Lin N, Wang Q, Liang P Sci Rep. 2024; 14(1):12283.

PMID: 38811828 PMC: 11137026. DOI: 10.1038/s41598-024-62836-z.


DEP domain containing 1 as a biomarker for poor prognosis in lung adenocarcinoma.

Li C, Zhu X Heliyon. 2024; 10(9):e30642.

PMID: 38765113 PMC: 11101781. DOI: 10.1016/j.heliyon.2024.e30642.


Integrated immunogenomic analysis of single-cell and bulk profiling reveals novel tumor antigens and subtype-specific therapeutic agents in lung adenocarcinoma.

Tian S, Luo M, Liao X, Zhang L, Zhang J, Zhang J Comput Struct Biotechnol J. 2024; 23:1897-1911.

PMID: 38721587 PMC: 11076661. DOI: 10.1016/j.csbj.2024.04.056.


References
1.
Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

2.
Shedden K, Taylor J, Enkemann S, Tsao M, Yeatman T, Gerald W . Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008; 14(8):822-7. PMC: 2667337. DOI: 10.1038/nm.1790. View

3.
Laack E, Nikbakht H, Peters A, Kugler C, Jasiewicz Y, Edler L . Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol. 2002; 20(21):4279-84. DOI: 10.1200/JCO.2002.08.067. View

4.
Marhelava K, Pilch Z, Bajor M, Graczyk-Jarzynka A, Zagozdzon R . Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. Cancers (Basel). 2019; 11(11). PMC: 6895894. DOI: 10.3390/cancers11111756. View

5.
Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M . Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. Cancer Immunol Res. 2019; 7(5):737-750. DOI: 10.1158/2326-6066.CIR-18-0436. View